Genetic Signatures
Market Cap
AU$179.3m
Last Updated
2021/06/14 08:18 UTC
Data Sources
Company Financials +
Executive Summary
Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in North America and Australia. More Details
Rewards
PE ratio (37.6x) is below the Life Sciences industry average (47x)
Risk Analysis
Earnings are forecast to decline by an average of 54.7% per year for the next 3 years
Snowflake Analysis
Flawless balance sheet and slightly overvalued.
Similar Companies
Share Price & News
How has Genetic Signatures's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GSS is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: GSS's weekly volatility (7%) has been stable over the past year.
Market Performance
7 Day Return
3.7%
GSS
7.3%
AU Life Sciences
0.6%
AU Market
1 Year Return
-36.3%
GSS
-16.6%
AU Life Sciences
32.6%
AU Market
Return vs Industry: GSS underperformed the Australian Life Sciences industry which returned -17.7% over the past year.
Return vs Market: GSS underperformed the Australian Market which returned 30.4% over the past year.
Shareholder returns
| GSS | Industry | Market | |
|---|---|---|---|
| 7 Day | 3.7% | 7.3% | 0.6% |
| 30 Day | 6.8% | 3.5% | 4.5% |
| 90 Day | -23.9% | -18.5% | 6.9% |
| 1 Year | -36.3%-36.3% | -16.6%-16.6% | 37.0%32.6% |
| 3 Year | 213.8%213.8% | 42.8%34.8% | 35.9%19.7% |
| 5 Year | 161.5%161.5% | -24.8%-33.5% | 71.3%38.1% |
Long-Term Price Volatility Vs. Market
How volatile is Genetic Signatures's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall St
Here's What Genetic Signatures Limited's (ASX:GSS) Shareholder Ownership Structure Looks Like1 month ago | Simply Wall St
Genetic Signatures Limited's (ASX:GSS) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?2 months ago | Simply Wall St
Did You Miss Genetic Signatures' (ASX:GSS) Whopping 543% Share Price Gain?Valuation
Is Genetic Signatures undervalued compared to its fair value and its price relative to the market?
37.6x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate GSS's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate GSS's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: GSS is good value based on its PE Ratio (37.6x) compared to the Global Life Sciences industry average (47x).
PE vs Market: GSS is poor value based on its PE Ratio (37.6x) compared to the Australian market (20.5x).
Price to Earnings Growth Ratio
PEG Ratio: GSS's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: GSS is good value based on its PB Ratio (3.5x) compared to the AU Life Sciences industry average (4.9x).
Future Growth
How is Genetic Signatures forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
-54.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GSS's earnings are forecast to decline over the next 3 years (-54.7% per year).
Earnings vs Market: GSS's earnings are forecast to decline over the next 3 years (-54.7% per year).
High Growth Earnings: GSS's earnings are forecast to decline over the next 3 years.
Revenue vs Market: GSS's revenue is expected to decline over the next 3 years (-0.3% per year).
High Growth Revenue: GSS's revenue is forecast to decline over the next 3 years (-0.3% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GSS's Return on Equity is forecast to be low in 3 years time (2.1%).
Past Performance
How has Genetic Signatures performed over the past 5 years?
17.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GSS has a high level of non-cash earnings.
Growing Profit Margin: GSS became profitable in the past.
Past Earnings Growth Analysis
Earnings Trend: GSS has become profitable over the past 5 years, growing earnings by 17.3% per year.
Accelerating Growth: GSS has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: GSS has become profitable in the last year, making it difficult to compare its past year earnings growth to the Life Sciences industry (44.2%).
Return on Equity
High ROE: GSS's Return on Equity (9.3%) is considered low.
Financial Health
How is Genetic Signatures's financial position?
Financial Position Analysis
Short Term Liabilities: GSS's short term assets (A$52.5M) exceed its short term liabilities (A$5.7M).
Long Term Liabilities: GSS's short term assets (A$52.5M) exceed its long term liabilities (A$280.0K).
Debt to Equity History and Analysis
Debt Level: GSS is debt free.
Reducing Debt: GSS has not had any debt for past 5 years.
Debt Coverage: GSS has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: GSS has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Genetic Signatures's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GSS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GSS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GSS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GSS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GSS's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
6.2yrs
Average management tenure
CEO
John Melki
10.42yrs
Tenure
AU$563,827
Compensation
Dr. John R. Melki, BSc, Ph.D. has been the Chief Executive Officer of Genetic Signatures Limited since 2011 and serves as its Managing Director and also served as its Principal Advisor. Dr. Melki has been ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD433.85K) is above average for companies of similar size in the Australian market ($USD283.14K).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: GSS's management team is seasoned and experienced (6.2 years average tenure).
Board Members
Experienced Board: GSS's board of directors are considered experienced (7.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Genetic Signatures Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Genetic Signatures Limited
- Ticker: GSS
- Exchange: ASX
- Founded: 2001
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$179.349m
- Shares outstanding: 142.91m
- Website: https://www.geneticsignatures.com
Number of Employees
Location
- Genetic Signatures Limited
- 7 Eliza Street
- Newtown
- Sydney
- New South Wales
- 2042
- Australia
Listings
Biography
Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in North America and Australia. The company designs and manufactures a suite of real-time polymerase chain reaction based product...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/06/14 08:18 |
| End of Day Share Price | 2021/06/11 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.